New Delhi: Opining that the drug power within the patch is to be regarded for fixation of the retail rate, the countrywide Pharmaceutical Pricing Authority (NPPA) panel has fixed the retail cost of each 37.5 sq. cm transdermal patch containing Diclofenac Diethylamine IP, manufactured by means of Azista Industries and marketed through Hetero Healthcare.
The retail rate of every 37.5 sq. cm transdermal patch containing Diclofenac Diethylamine IP 100 mg for Azista Industries (brand) and Hetero Healthcare (marketer) has been set at Rs. 31.25 per patch, apart from GST.
This advice came all through the 38th assembly of the 'Multidisciplinary Committee of consultants' assembly, held on January 24, 2022, beneath the convenorship of Dr. Vinod Kotwal, Member Secretary, via video-conferencing.
Diclofenac is a phenylacetic acid derivative and a non-steroidal anti-inflammatory drug (NSAID). It acts through inhibiting cyclooxygenase (COX)-1 and-2, which might be the enzymes accountable for producing prostaglandins (PGs). PGs make a contribution to inflammation and pain signalling. Diclofenac, like different NSAIDs, is frequently used as first line remedy for acute and persistent pain and inflammation from lots of factors.
Transdermal patches are patches that adhere to the dermis as a means to convey medicine. They supply a selected, predetermined dose of remedy which is absorbed in the course of the epidermis and into the bloodstream. Transdermal diclofenac is used to treat brief-term ache as a result of minor strains, sprains, and bruises in adults and children 6 years of age or older.
At a recent Multidisciplinary Committee of specialists meeting, the panel stated the retail expense fixation of a 37.5 sq cm transdermal patch containing Diclofenac Diethylamine IP 100mg and followed that the records for the patch having Diclofenac IP 100mg (with out citing the patch measurement) became obtainable in the Pharmatrac database and the proposed retail expense in line with the data for the month of may also 2021 came to Rs. 39.sixty five per patch, with the exception of GST.
The Committee further mentioned that Hetero Healthcare has sought a retail expense of Rs. 31.25 per patch, aside from GST.
After exact deliberation, the Committee opined that the drug power (i.e., Diclofenac 100mg) within the patch is to be considered for fixation of the retail cost.
The size of the patch isn't primary because the therapeutic efficacy depends upon the dosage energy of the drug, the committee mentioned.
as a result, the Committee considered the retail expense of Rs. 39.65 per patch aside from GST because the labored out fee and recommended the retail fee of each and every 37.5 sq. cm transdermal patch containing Diclofenac Diethylamine IP a hundred mg for Azista Industries (company) and M/s Hetero Healthcare (marketer) at Rs. 31.25 per patch, apart from GST, being lessen than the worked out rate.
No comments:
Post a Comment